AckermanBHOlsenKMKennedyEE, Disposition of 3-hydroxyquinidine in patients receiving initial intravenous quinidine gluconate for electrophysiology testing of ventricular tachycardia. DICP Ann Pharmacother1989; 23: 375–8.
2.
VozehSBindschedlerMHuy-RiemHKaufmannGGuentertTWFollathF. Pharmacodynamics of 3-hydroxyquinidine alone and in combination with quinidine in healthy persons. Am J Cardiol1987; 59: 681–4.
3.
RakhitAHolfordNHGGuentertTWMaloneyKRiegelmannS. Pharmacokinetics of quinidine and three of its metabolites in man. J Pharmacokinet Biopharm1984; 12: 12–21.
4.
The Cardiac Arrhythmia Suppression Trial Investigators. [Special Report]. Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med1989; 321: 406–12.
5.
AckermanBHOlsenKMKennedyEE, Comparison of disposition parameters obtained by two assay methods for quinidine gluconate in patients with ventricular tachycardia. Pharmacotherapy1989; 9: 220–5.
